Immutep Limited (IMMP)
After hours:
| Previous Close | 2.1300 |
| Open | 2.1400 |
| Bid | 2.1400 x 400 |
| Ask | 2.1800 x 400 |
| Day's Range | 2.1200 - 2.1800 |
| 52 Week Range | 1.5800 - 3.3400 |
| Volume | |
| Avg. Volume | 403,996 |
| Market Cap | 325.958M |
| Beta (5Y Monthly) | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2000 |
| Earnings Date | Jul 28, 2024 - Aug 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.01 |
GlobeNewswireImmutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancerTACTI-004 registrational trial will enrol ~750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy SYDNEY, AUSTRALIA, July 22, 2024 (GLOBE NE
- GlobeNewswire
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761. IMP761 is the world’s
ZacksImmutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
